Rhenium Coordination Compounds as Promising Radiopharmaceuticals

 Radiopharmaceuticals are compounds with radioactive isotopes that are used in nuclear medicine to diagnose and treat patients. Rhenium compounds have attracted considerable interest in bioinorganic chemistry, particularly for their potential applications in cancer therapy. Rhenium, a rare transition metal, is noted for its distinct oxidation states and diverse coordination chemistry, which enable the creation of a wide range of complexes. The theragnostic potential of rhenium coordination compounds stems from their capacity to be recognized with different isotopes, allowing for imaging and therapeutic uses. Due to their versatility, rhenium coordination compounds have been studied as radiopharmaceuticals for diagnostic and therapeutic applications. Rhenium-based imaging agents, notably those tagged with the radioactive isotope 188Re, have shown promise in a variety of nuclear imaging techniques, including single-photon emission computed tomography and positron emission tomography. Rhenium(I) complexes are a promising family of anticancer medicines that have various advantages over traditional platinum-based treatments such as cisplatin. Their unique modes of action, enhanced potency in specific cancer cell lines, and ability to overcome drug resistance make them attractive candidates in cancer therapy. Furthermore, rhenium compounds may have a more favorable side effect profile and improved biodistribution, resulting in higher patient tolerance. Rhenium compounds have promise in the creation of targeted cancer medicines. Their distinct chemical features and modes of action provide substantial advantages over standard chemotherapeutics, particularly in terms of cancer cell selectivity and decreased side effects. Rhenium complexes' propensity to cause apoptosis and other forms of programmed cell death, together with their potential for combination therapy, makes them promising prospects in the fight against cancer.